Enovis (ENOV) Competitors $32.36 +0.01 (+0.02%) Closing price 03:59 PM EasternExtended Trading$32.38 +0.02 (+0.06%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENOV vs. STVN, GKOS, NARI, INSP, IRTC, BLCO, TMDX, SLNO, NVST, and PRCTShould you be buying Enovis stock or one of its competitors? The main competitors of Enovis include Stevanato Group (STVN), Glaukos (GKOS), Inari Medical (NARI), Inspire Medical Systems (INSP), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), Envista (NVST), and PROCEPT BioRobotics (PRCT). These companies are all part of the "medical equipment" industry. Enovis vs. Stevanato Group Glaukos Inari Medical Inspire Medical Systems iRhythm Technologies Bausch + Lomb TransMedics Group Soleno Therapeutics Envista PROCEPT BioRobotics Enovis (NYSE:ENOV) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, community ranking, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends. Which has more risk and volatility, ENOV or STVN? Enovis has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Do analysts rate ENOV or STVN? Enovis currently has a consensus price target of $58.00, suggesting a potential upside of 79.26%. Given Enovis' higher probable upside, equities research analysts clearly believe Enovis is more favorable than Stevanato Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enovis 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86 Is ENOV or STVN more profitable? Stevanato Group has a net margin of 10.47% compared to Enovis' net margin of -5.95%. Stevanato Group's return on equity of 9.86% beat Enovis' return on equity.Company Net Margins Return on Equity Return on Assets Enovis-5.95% 4.39% 2.80% Stevanato Group 10.47%9.86%5.79% Do insiders & institutionals have more ownership in ENOV or STVN? 98.4% of Enovis shares are held by institutional investors. 2.7% of Enovis shares are held by company insiders. Comparatively, 0.7% of Stevanato Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community favor ENOV or STVN? Enovis received 4 more outperform votes than Stevanato Group when rated by MarketBeat users. Likewise, 66.04% of users gave Enovis an outperform vote while only 63.27% of users gave Stevanato Group an outperform vote. CompanyUnderperformOutperformEnovisOutperform Votes3566.04% Underperform Votes1833.96% Stevanato GroupOutperform Votes3163.27% Underperform Votes1836.73% Does the media prefer ENOV or STVN? In the previous week, Enovis and Enovis both had 7 articles in the media. Stevanato Group's average media sentiment score of 1.74 beat Enovis' score of 1.48 indicating that Stevanato Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enovis 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stevanato Group 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has better earnings and valuation, ENOV or STVN? Stevanato Group has lower revenue, but higher earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnovis$2.15B0.86-$33.26M-$13.95-2.32Stevanato Group$1.12B6.12$157.62M$0.5144.53 SummaryStevanato Group beats Enovis on 10 of the 17 factors compared between the two stocks. Get Enovis News Delivered to You Automatically Sign up to receive the latest news and ratings for ENOV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENOV vs. The Competition Export to ExcelMetricEnovisSurgical appliances & supplies IndustryMedical SectorNYSE ExchangeMarket Cap$1.85B$9.45B$5.33B$19.30BDividend YieldN/A1.62%5.21%3.84%P/E Ratio-14.7720.7426.7134.53Price / Sales0.8661.22386.1334.83Price / Cash6.8619.6738.2517.51Price / Book0.525.096.774.69Net Income-$33.26M$284.66M$3.23B$1.02B7 Day Performance-9.77%-1.18%1.80%-1.74%1 Month Performance-0.76%1.44%11.10%7.50%1 Year Performance-36.61%-21.91%17.11%4.15% Enovis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENOVEnovis3.2537 of 5 stars$32.36+0.0%$58.00+79.3%-35.7%$1.85B$2.15B-14.776,800Positive NewsSTVNStevanato Group1.3372 of 5 stars€23.64-1.5%N/A+24.6%$7.16B$1.10B50.304,650Positive NewsGKOSGlaukos4.6181 of 5 stars$94.57+5.1%$134.67+42.4%-12.5%$5.40B$404.52M-32.95780Positive NewsAnalyst RevisionNARIInari Medical0.5859 of 5 stars$79.97flat$69.22-13.4%N/A$4.68B$493.63M-59.24800INSPInspire Medical Systems4.67 of 5 stars$156.54+3.5%$211.91+35.4%-4.0%$4.62B$840.11M90.49760Positive NewsIRTCiRhythm Technologies1.2487 of 5 stars$137.80+0.1%$128.55-6.7%+52.9%$4.40B$618.59M-37.861,790Positive NewsAnalyst ForecastBLCOBausch + Lomb4.1301 of 5 stars$11.91+5.6%$15.50+30.2%-22.8%$4.21B$4.83B-13.0812,500Gap UpTMDXTransMedics Group1.2881 of 5 stars$118.73+6.5%$126.70+6.7%-12.4%$4.02B$488.23M126.31210Positive NewsGap DownSLNOSoleno Therapeutics4.8494 of 5 stars$76.70-0.1%$106.78+39.2%+65.6%$3.87BN/A-23.1030News CoveragePositive NewsNVSTEnvista4.174 of 5 stars$18.56+5.5%$20.08+8.2%-9.2%$3.15B$2.50B-2.8612,700Positive NewsGap DownPRCTPROCEPT BioRobotics2.916 of 5 stars$54.44+2.5%$90.00+65.3%-17.6%$3.01B$249.12M-27.92430Positive News Related Companies and Tools Related Companies Stevanato Group Competitors Glaukos Competitors Inari Medical Competitors Inspire Medical Systems Competitors iRhythm Technologies Competitors Bausch + Lomb Competitors TransMedics Group Competitors Soleno Therapeutics Competitors Envista Competitors PROCEPT BioRobotics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ENOV) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enovis Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enovis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ENOV Stock Free ENOV Stock Alerts